4D Molecular Therapeutics Inc.

10.40-0.2500-2.35%Vol 157.17K1Y Perf -62.14%
Aug 11th, 2022 16:00 DELAYED
BID10.25 ASK10.56
Open10.62 Previous Close10.65
Pre-Market- After-Market10.40
 - -  - -%
Target Price
21.67 
Analyst Rating
Strong Buy 1.00
Potential %
108.37 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★★★     57.08
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
★★★★     60.24
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
16.48 
Earnings Rating
Market Cap335.91M 
Earnings Date
11th Aug 2022
Alpha-0.08 Standard Deviation0.15
Beta1.26 

Today's Price Range

10.2511.06

52W Range

5.3236.14

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
-9.41%
1 Month
25.91%
3 Months
10.40%
6 Months
-30.53%
1 Year
-62.14%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
FDMT10.40-0.2500-2.35
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
-
-471.80
-454.10
-5 729.60
-
RevenueValueIndustryS&P 500US Markets
2.68M
0.08
15.23
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.73-0.82-12.33
Q04 2021-0.82-0.85-3.66
Q03 2021-0.83-0.821.20
Q02 2021-0.71-0.2860.56
Q01 2021--0.61-
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.78
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume157.17K
Shares Outstanding32.30K
Shares Float25.87M
Trades Count2.66K
Dollar Volume1.66M
Avg. Volume188.64K
Avg. Weekly Volume160.71K
Avg. Monthly Volume147.65K
Avg. Quarterly Volume257.57K

4D Molecular Therapeutics Inc. (NASDAQ: FDMT) stock closed at 10.4 per share at the end of the most recent trading day (a -2.35% change compared to the prior day closing price) with a volume of 157.17K shares and market capitalization of 335.91M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 78 people. 4D Molecular Therapeutics Inc. CEO is David Kirn.

The one-year performance of 4D Molecular Therapeutics Inc. stock is -62.14%, while year-to-date (YTD) performance is -52.6%. FDMT stock has a five-year performance of %. Its 52-week range is between 5.32 and 36.14, which gives FDMT stock a 52-week price range ratio of 16.48%

4D Molecular Therapeutics Inc. currently has a PE ratio of -3.60, a price-to-book (PB) ratio of 1.10, a price-to-sale (PS) ratio of 115.95, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -27.31%, a ROC of -28.48% and a ROE of -30.18%. The company’s profit margin is -%, its EBITDA margin is -454.10%, and its revenue ttm is $2.68 Million , which makes it $0.08 revenue per share.

Of the last four earnings reports from 4D Molecular Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.78 for the next earnings report. 4D Molecular Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for 4D Molecular Therapeutics Inc. is Strong Buy (1), with a target price of $21.67, which is +108.37% compared to the current price. The earnings rating for 4D Molecular Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

4D Molecular Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

4D Molecular Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 48.27, ATR14 : 0.83, CCI20 : 49.48, Chaikin Money Flow : 0.14, MACD : 0.58, Money Flow Index : 51.45, ROC : -2.89, RSI : 59.37, STOCH (14,3) : 52.34, STOCH RSI : 0.00, UO : 57.72, Williams %R : -47.66), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of 4D Molecular Therapeutics Inc. in the last 12-months were: David Schaffer (Sold 33 244 shares of value $1 060 518 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

4D Molecular Therapeutics Inc.

4D Molecular Therapeutics Inc is a development stage precision gene therapy company. It engages in developing a broad pipeline of transformative gene therapy product candidates designed to treat patients suffering from lysosomal storage diseases, lung diseases, muscular dystrophies, and ophthalmic diseases. The AAV vectors are designed to provide targeted delivery by routine clinical routes, efficient transduction, reduced immunogenicity and resistance to pre-existing antibodies which enable to develop gene therapies.

CEO: David Kirn

Telephone: +1 510 505-2680

Address: 5858 Horton Street, Emeryville 94608, CA, US

Number of employees: 78

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

51%49%

Bearish Bullish

55%45%

TipRanks News for FDMT

Fri, 13 May 2022 12:40 GMT 4D Molecular Therapeutics (FDMT) Receives a Buy from SVB Securities

- TipRanks. All rights reserved.

News

Stocktwits